Answers are grounded in this paper and cite their sources.
The treatment of peripheral T-cell lymphomas is challenging, as they often display a severe prognosis and lack effective treatment strategies. We will try to answer three burning questions: can we differentiate the initial treatment based on the histotype and the clinical presentation of peripheral T-cell lymphoma patients? Do we require an autologous stem cell transplantation in all patients? Is there room for improvement in the setting of relapsed and refractory disease?
No takes yet. Share an insight, caveat, or question.
Broccoli et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: